{"url_path":"/sec/krys/8-k/2026-07-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1711279/0001711279-26-000050-index.html","accession_number":"0001711279-26-000050","cik":"0001711279","ticker":"KRYS","issuer_name":"Krystal Biotech, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1711279/0001711279-26-000050-index.html","primary_entity_key":"0001711279","primary_entity_name":"Krystal Biotech, Inc."},"word_count":450,"has_tables":true,"body_markdown":"Item 8.01    Other Events.\n\nOn July 21, 2026, Krystal Biotech, Inc. (the “Company”) filed with the U.S. Patent and Trademark Office a response to an Office Action in connection with a published patent application relating to KB801, the Company’s investigational gene therapy product candidate for the treatment of neurotrophic keratitis. In support of the patentability of the claims, the response included data from a patient who received KB801 in a discontinued clinical study and experienced complete closure of a persistent corneal epithelial defect. The Company discontinued the clinical study in order to advance KB801 into a pivotal trial and no safety concerns or serious adverse events were observed in patients treated in the study.\n\nThe Company did not previously disclose the single-patient observation described above and is making this disclosure now solely to ensure that all investors and other stakeholders have equal access to it as it becomes publicly available through the patent prosecution record.\n\nThe observation described above reflects the experience of a single patient, does not represent top-line results of any clinical trial, and no conclusions regarding the safety or efficacy of KB801 should be drawn from it. The Company does not currently intend to provide subject-level updates from the discontinued clinical study and expects to report results from its pivotal trial of KB801 in the ordinary course.\n\nThe information in this Item 8.01 and the copy of the image of the corneal epithelial defect closure from the patent prosecution record that is attached to this Current Report on Form 8-K as Exhibit 99.1 shall not be (i) deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended , or otherwise subject to the liabilities of that section, or (ii) incorporated by reference into any filing with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.\n\nForward-Looking Statements\n\nThis Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the timing of reporting results from the Company’s pivotal trial of KB801. Forward-looking statements are subject to known and unknown risks and uncertainties, including that results from a single patient or a discontinued study are not necessarily indicative of results in any pivotal or other trial, and the other risks and uncertainties described under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statement, except as required by law."}